Stay updated on MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety
Sign up to get notified when there's something new on the MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety page.

Latest updates to the MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study protocols and inclusion criteria for a clinical trial on tildrakizumab for plaque psoriasis, while a new version number has been added.SummaryDifference27%
- Check35 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check42 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check78 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check93 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety
Enter your email address, and we'll notify you when there's something new on the MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety page.